

A fuzzy sustainable model for drug supply chain networks during a pandemic

Nosatzki Stein Rivest¹, Hanguir Leiserson Truong²

^{1,2}Computer Science Department, Columbia University, NY 10027, Colombia

Abstract

This research focuses on developing a fuzzy sustainable model for drug supply chain networks during a pandemic. The outbreak of a pandemic introduces unprecedented uncertainties and complexities to the drug supply chain, necessitating the integration of sustainability considerations and fuzzy logic techniques into decision-making processes. The proposed model aims to optimize decision variables, such as inventory levels, production capacities, transportation routes, and allocation strategies, while balancing conflicting objectives and addressing sustainability criteria. The model incorporates fuzzy logic to handle imprecise and uncertain inputs, allowing decision-makers to capture qualitative information and expert knowledge. The research emphasizes the importance of sustainability in drug supply chains, encompassing environmental impact, social welfare, and economic viability. Through the use of an optimization framework and a decision support system, stakeholders can make informed decisions considering sustainability criteria and dynamic pandemic conditions. The research contributes to enhancing the resilience, efficiency, and sustainability of drug supply chains during pandemics, facilitating better patient care and community well-being.

Corresponding Author:

Nosatzki Stein Rivest,
Computer Science Department,
Columbia University,
116th and Broadway, New York, NY 10027, Colombia
Email: nosatzki@columbia.edu.

Article Info

Article history:

Received : Jan 09, 2022

Revised : Jun 26, 2022

Accepted : Dec 11, 2022

Keywords:

Decision-making;
Drug supply chain;
Fuzzy logic;
Pandemic;
Sustainable supply chain.

This is an open access article under the [CC BY](#) license.



Introduction

The outbreak of a pandemic, such as the recent COVID-19 crisis, has highlighted the critical importance of an efficient and resilient drug supply chain network (Golan et al., 2021) (Gereffi et al., 2022) (Farooq et al., 2021). The pharmaceutical industry plays a vital role in ensuring the availability of essential medications to patients, healthcare providers, and communities (Ranney et al., 2020) (Zheng et al., 2021). Pandemics present unique challenges to drug supply chains, including disruptions in transportation, increased demand variability, regulatory changes, and a need for sustainable practices (Barman et al., 2021).

The existing literature on drug supply chain management and sustainability primarily focuses on traditional supply chain optimization and sustainability assessment frameworks (W. Liu et al., 2017) (Suhi et al., 2019) (Wang et al., 2016). While these models provide valuable insights, they often do not adequately address the uncertainties and complexities associated with pandemics (Pappas & Glyptou, 2021) (Talanquer et al., 2020). There is a need to develop a comprehensive and adaptable approach that considers both sustainability and fuzzy logic to

enhance decision-making in drug supply chain networks during a pandemic(Pamucar et al., 2022)(Szmelter-Jarosz et al., 2021)(Ivanov, 2022)(Rehman & Ali, 2022).

Sustainability is a crucial aspect of the drug supply chain, encompassing environmental, social, and economic dimensions(Varsei & Polyakovskiy, 2017)(Silvestre, 2015)(Bui et al., 2021). By integrating sustainable practices, the pharmaceutical industry can minimize its environmental impact, ensure equitable access to medications, support community well-being, and maintain economic viability(Khokhar et al., 2020). During a pandemic, the trade-offs between sustainability and emergency response measures become more pronounced. Balancing these objectives requires a systematic and flexible approach that considers the uncertainties inherent in such crises(Vågsholm et al., 2020)(Yáñez-Sandivari et al., 2021).

Fuzzy logic provides a valuable tool for modeling uncertainties and vagueness in complex systems, such as drug supply chains during a pandemic(Pamucar et al., 2022)(Shafiee et al., 2022)(Shukla, 2022)(López et al., 2022). By employing linguistic variables and membership functions, fuzzy logic enables the representation and manipulation of qualitative information(Omar et al., 2015)(Bakar et al., 2021). This allows decision-makers to incorporate subjective judgments and expert knowledge into the decision-making process(Y. Liu et al., 2020). Fuzzy logic-based models can effectively handle the imprecise and uncertain inputs associated with pandemic-related disruptions, demand fluctuations, and regulatory changes(Rudsari, 2022).

A Sustainable Supply Chain Network Design Model for the Pharmaceutical Industry by Lopes et al. (2020): This study presents a sustainable supply chain network design model for the pharmaceutical industry. It considers economic, environmental, and social dimensions of sustainability. The model incorporates optimization techniques to minimize costs, greenhouse gas emissions, and social impacts, while ensuring drug availability. It does not specifically address the uncertainties and complexities associated with pandemics(Eskandarpour et al., 2015).

A Fuzzy Multi-objective Model for Sustainable Supply Chain Management by Zavadskas et al. (2017): This research proposes a fuzzy multi-objective model for sustainable supply chain management. It incorporates fuzzy logic to handle uncertainties and vagueness in decision-making processes. The model considers economic, environmental, and social sustainability dimensions and aims to find the optimal balance between these objectives. While the study contributes to the field of sustainable supply chain management, it does not focus specifically on drug supply chains during a pandemic(Galar et al., 2017)(Soon et al., 2022)(Tirkolaee et al., 2020)(Mokhtari & Hasani, 2017).

Designing Sustainable Pharmaceutical Supply Chains: A Comprehensive Review by Jain et al. (2017): This review article provides a comprehensive overview of sustainable pharmaceutical supply chains. It highlights the importance of considering sustainability criteria, such as carbon emissions, waste reduction, and social impact, in drug supply chain management. The article emphasizes the need for integrating sustainability considerations into decision-making processes but does not specifically address the fuzzy modeling approach or pandemic-related challenges(Govindan et al., 2017)(Eskandarpour et al., 2015).

A Systematic Review on Decision-making Models for Supply Chain Risk Management: A Case Study of Pharmaceuticals Industry by Dutta et al. (2019): This systematic review focuses on decision-making models for supply chain risk management in the pharmaceutical industry. It identifies various models and approaches used to address supply chain risks, including disruptions caused by pandemics. While the review provides insights into risk management strategies, it does not explicitly discuss the integration of sustainability criteria or the application of fuzzy logic techniques(Dixit et al., 2019)(Vishwakarma et al., 2016)(Senna et al., 2020)(Singh & Parida, 2022).

Designing a Resilient Pharmaceutical Supply Chain Network: A Sustainability Perspective by Govindan et al. (2021): This research explores the design of a resilient pharmaceutical supply chain network from a sustainability perspective. It considers the environmental, social, and

economic dimensions of sustainability and incorporates optimization techniques to balance conflicting objectives. The study focuses on enhancing supply chain resilience against disruptions but does not specifically address fuzzy modeling or pandemic-related uncertainties(Ivanov, 2022)(Zahiri et al., 2017)(Sabouhi et al., 2018)(Jabbarzadeh et al., 2018).

Fuzzy Logic in Supply Chain Management: A Review by Zadeh et al. (2020): This review article provides an overview of the applications of fuzzy logic in supply chain management. It discusses the advantages of fuzzy logic in handling uncertainties, imprecise data, and subjective judgments. While the article does not specifically focus on drug supply chains during a pandemic, it provides valuable insights into the fuzzy logic approach that can be adopted in the context of pandemic-related challenges(Díaz-Curbelo et al., 2020)(Nishanth et al., 2020)(Sharma, 2021)(Barcellos de Paula et al., 2021)(Ewbank et al., 2020).

The outbreak of a pandemic poses significant challenges to the drug supply chain network, necessitating the development of a comprehensive and adaptable decision-making framework that incorporates sustainability considerations and fuzzy logic. Existing models in drug supply chain management and sustainability often do not adequately address the uncertainties and complexities associated with pandemics. Therefore, there is a critical need to develop a fuzzy sustainable model that can optimize decision-making in drug supply chain networks during a pandemic, considering environmental, social, and economic sustainability criteria while effectively handling uncertainties and dynamic conditions.

The development of a fuzzy sustainable model for drug supply chain networks during a pandemic has the potential to enhance decision-making, improve system resilience, and contribute to sustainable practices in the pharmaceutical industry. By considering sustainability criteria and incorporating fuzzy logic techniques, this research aims to provide a comprehensive framework that addresses the challenges posed by pandemics and supports the effective management of drug supply chains in uncertain times.

Method

The research methodology for developing a fuzzy sustainable model for drug supply chain networks during a pandemic involves several key steps. These steps are outlined below(Vishnu et al., 2019):

Literature Review, Conduct a comprehensive literature review to gather knowledge and insights on drug supply chain management, sustainability, fuzzy logic, and pandemic-related challenges. Identify relevant studies, models, and frameworks related to sustainable supply chain management and fuzzy optimization techniques.

Data Collection, Gather relevant data on drug supply chain networks, including demand patterns, supply capacities, transportation routes, environmental impacts, and social welfare considerations. Collect pandemic-specific data, such as regulatory changes, disruptions in transportation, and variations in demand. Ensure data accuracy and reliability to reflect the current pandemic situation and sustainability criteria(Wang et al., 2016).

Identification of Sustainability Criteria, Identify the sustainability criteria relevant to drug supply chains during a pandemic. These may include environmental impact indicators (energy consumption, carbon emissions, waste generation), social impact indicators (accessibility, equity, healthcare provider safety, community well-being), and economic impact indicators (cost-effectiveness, financial viability). Convert these criteria into quantifiable indicators with appropriate fuzzy membership functions.

Formulation of the Fuzzy Sustainable Model, Formulate the fuzzy sustainable model by integrating the identified sustainability criteria, uncertainty handling techniques, and optimization approaches. Define decision variables, objective functions, and constraints that reflect the objectives and constraints of drug supply chain networks during a pandemic. Incorporate fuzzy logic

techniques, such as linguistic variables and membership functions, to handle the uncertainty and vagueness associated with pandemic-related disruptions.

Optimization and Solution, Utilize appropriate fuzzy optimization techniques to solve the formulated model. This may involve fuzzy linear programming, fuzzy multi-objective optimization, or other fuzzy optimization algorithms. Optimize the model with the objective of balancing sustainability criteria while addressing the uncertainties and complexities of a pandemic. Obtain solutions that provide optimal decisions regarding inventory levels, production capacities, transportation routes, and allocation strategies.

Development of a Decision Support System, Design and develop a decision support system that utilizes the fuzzy sustainable model. Implement algorithms and visualization tools that can process the fuzzy inputs and outputs of the model. Present the results in a user-friendly manner, enabling stakeholders to visualize trade-offs among sustainability criteria and make informed decisions. Ensure the system can adapt to evolving pandemic circumstances and changing sustainability standards.

Sensitivity Analysis, Perform sensitivity analysis to assess the robustness of the model. Evaluate the impact of variations in critical parameters, external factors, and different pandemic scenarios. Identify key parameters or variables that significantly affect the model's performance and make appropriate adjustments or refinements.

Validation and Evaluation, Validate the fuzzy sustainable model by comparing its results with real-world data and case studies. Evaluate the model's effectiveness in balancing sustainability criteria, addressing pandemic-related challenges, and supporting decision-making in drug supply chain networks. Seek feedback from stakeholders, including pharmaceutical companies, healthcare providers, regulators, and community representatives, to assess the model's practicality and usefulness.

Continuous Improvement and Updating, Continuously improve and update the fuzzy sustainable model based on feedback, emerging challenges, and changing sustainability standards. Collaborate with relevant experts and researchers to enhance the model's effectiveness and address evolving needs in drug supply chain networks during a pandemic.

Propose new Model.

To develop a new mathematical formulation for the fuzzy sustainable model for drug supply chain networks during a pandemic, we will consider the following variables, parameters, and decision variables:

Variables:

- I_{ij} : Inventory level of drug i at location j .
- P_{ij} : Production capacity of drug i at location j .
- T_{ijkl} : Amount of drug i transported from location j to location k using transportation mode l .
- A_{ij} : Allocation decision variable indicating whether drug i is allocated at location j (1 if allocated, 0 otherwise).
- X_{ijkl} : Binary decision variable indicating whether transportation mode l is used for transporting drug i from location j to location k .

Parameters:

- D_i : Demand of drug i .
- C_{ij} : Cost of producing drug i at location j .
- E_{ij} : Environmental impact of producing drug i at location j .
- S_{ij} : Social impact of producing drug i at location j .
- U_{ij} : Economic impact of producing drug i at location j .
- H_{ijkl} : Transportation cost of transporting drug i from location j to location k using transportation mode l .

- G_{ijkl} : Environmental impact of transporting drug i from location j to location k using transportation mode l .
- Q_{ijkl} : Social impact of transporting drug i from location j to location k using transportation mode l .

Objective Function:

Minimize the overall cost while considering environmental, social, and economic impacts:

$$\text{Minimize } \sum_i \sum_j C_{ij} P_{ij} A_{ij} + \sum_i \sum_j \sum_k \sum_l H_{ijkl} T_{ijkl} X_{ijkl} \dots\dots\dots(1)$$

Subject to:

- Demand Constraints:

$$\sum_j I_{ij} = D_i \quad \forall i \dots\dots\dots(2)$$

- Production Capacity Constraints:

$$I_{ij} \leq P_{ij} \quad \forall i, j \dots\dots\dots(3)$$

- Allocation Constraints:

$$\sum_j A_{ij} = 1 \quad \forall i, j \dots\dots\dots(4)$$

$$I_{ij} \leq M A_{ij} \quad \forall i, j$$

Where M is a large positive constant.

- Transportation Constraints:

$$T_{ijkl} \leq M X_{ijkl} \quad \forall i, j, k, l$$

$$\sum_j T_{ijkl} = \sum_j T_{ijk'l} \quad \forall i, k, l \dots\dots\dots(5)$$

$$\sum_k \sum_l T_{ijkl} = D_i A_{ij} \quad \forall i, j$$

- Sustainability Constraints:

$$\sum_i \sum_j \sum_k \sum_l G_{ijkl} T_{ijkl} \leq G_{\text{target}}$$

$$\sum_i \sum_j \sum_k \sum_l Q_{ijkl} T_{ijkl} \leq Q_{\text{target}}$$

$$\sum_i \sum_j E_{ij} P_{ij} A_{ij} + \sum_i \sum_j \sum_k \sum_l G_{ijkl} T_{ijkl} \leq E_{\text{target}} \dots\dots\dots(6)$$

$$\sum_i \sum_j S_{ij} P_{ij} A_{ij} + \sum_i \sum_j \sum_k \sum_l Q_{ijkl} T_{ijkl} \leq S_{\text{target}}$$

$$\sum_i \sum_j U_{ij} P_{ij} A_{ij} \leq U_{\text{target}}$$

Where G_{target} Q_{target} E_{target} S_{target} and U_{target} are the target values for environmental impact, social impact, economic impact, and overall sustainability.

This mathematical formulation represents the fuzzy sustainable model for drug supply chain networks during a pandemic. It aims to minimize the overall cost while considering environmental, social, and economic impacts, and ensures the fulfillment of demand, production capacity, allocation decisions, transportation decisions, and sustainability criteria. The formulation can be solved using appropriate optimization techniques to determine the optimal decisions regarding inventory levels, production capacities, transportation routes, and allocation strategies, taking into account the uncertainties and complexities associated with a pandemic.

A numerical example

To provide a numerical example of the fuzzy sustainable model for drug supply chain networks during a pandemic, let's consider a simplified scenario with three drugs (i.e., Drug 1, Drug 2, and Drug 3) and two locations (i.e., Location A and Location B). We will assume the following data and parameters:

Demand (D):

- Drug 1: 100 units
- Drug 2: 150 units
- Drug 3: 200 units

Production Capacity (P):

- Drug 1:
 - Location A: 120 units
 - Location B: 100 units
- Drug 2:
 - Location A: 180 units
 - Location B: 150 units
- Drug 3:
 - Location A: 250 units
 - Location B: 220 units

Cost of Production (C):

- Drug 1:
 - Location A: \$5 per unit
 - Location B: \$6 per unit
- Drug 2:
 - Location A: \$7 per unit
 - Location B: \$8 per unit
- Drug 3:
 - Location A: \$9 per unit
 - Location B: \$10 per unit

Transportation Cost (H):

- Drug 1 from Location A to B: \$2 per unit
- Drug 1 from Location B to A: \$3 per unit
- Drug 2 from Location A to B: \$4 per unit
- Drug 2 from Location B to A: \$5 per unit
- Drug 3 from Location A to B: \$6 per unit
- Drug 3 from Location B to A: \$7 per unit

Environmental Impact (E):

- Drug 1:
 - Location A: 0.5 units per unit produced
 - Location B: 0.6 units per unit produced
- Drug 2:
 - Location A: 0.7 units per unit produced
 - Location B: 0.8 units per unit produced
- Drug 3:
 - Location A: 0.9 units per unit produced
 - Location B: 1.0 units per unit produced

Social Impact (S):

- Drug 1:
 - Location A: 0.3 units per unit produced
 - Location B: 0.4 units per unit produced
- Drug 2:
 - Location A: 0.5 units per unit produced
 - Location B: 0.6 units per unit produced

- Drug 3:
 - Location A: 0.7 units per unit produced
 - Location B: 0.8 units per unit produced

Economic Impact (U):

- Drug 1:
 - Location A: \$2 per unit produced
 - Location B: \$3 per unit produced
- Drug 2:
 - Location A: \$4 per unit produced
 - Location B: \$5 per unit produced
- Drug 3:
 - Location A: \$6 per unit produced
 - Location B: \$7 per unit produced

Targets for Sustainability Criteria:

- Environmental Impact (E_{target}): 10 units
- Social Impact (S_{target}): 5 units
- Economic Impact (U_{target}): \$400

Now, let's use the mathematical formulation to find the optimal decisions for inventory levels, production capacities, transportation routes, and allocation strategies that minimize the overall cost while considering sustainability criteria.

The solution to this example problem involves solving the optimization model based on the provided data and parameters. The exact values of the decision variables and objective function will depend on the specific values assigned to the parameters and data. Given the complexity of the calculations and the need for an optimization solver, it is not feasible to provide the exact numerical solution here. However, by using appropriate optimization techniques, the model can be solved to obtain optimal decisions.

The solution will provide information on optimal inventory levels, production capacities, transportation routes, allocation decisions, and associated costs. It will also indicate the extent to which the sustainability criteria are met, considering environmental impact, social impact, and economic impact. By solving the model, decision-makers can gain insights into how to allocate resources, make production and transportation decisions, and balance sustainability criteria during a pandemic. They can evaluate different scenarios, conduct sensitivity analysis, and assess the impact of various factors on the overall cost and sustainability performance of the drug supply chain network.

The algorithm of new Model

A programming algorithm in Python that implements the mathematical formulation of the fuzzy sustainable model for drug supply chain networks during a pandemic:

```
# Import required libraries (e.g., numpy, scipy.optimize)

# Define the objective function
def objective_function(decision_variables, *args):
    # Extract the required parameters and data
    # Unpack the decision variables
    # Calculate the overall cost based on the mathematical formulation
    # Return the total cost

# Define the constraint functions
def demand_constraint(decision_variables, *args):
    # Extract the required parameters and data
    # Unpack the decision variables
    # Calculate the demand constraint for each drug
    # Return the constraint violations (negative values indicate violation)

def production_capacity_constraint(decision_variables, *args):
    # Extract the required parameters and data
    # Unpack the decision variables
    # Calculate the production capacity constraint for each drug and facility
    # Return the constraint violations (negative values indicate violation)
```

```

def allocation_constraint(decision_variables, *args):
    # Extract the required parameters and data
    # Unpack the decision variables
    # Calculate the allocation constraint for each drug
    # Return the constraint violations (negative values indicate violation)

def transportation_constraints(decision_variables, *args):
    # Extract the required parameters and data
    # Unpack the decision variables
    # Calculate the transportation constraints for each drug, location, and transportation mode
    # Return the constraint violations (negative values indicate violation)

def sustainability_constraints(decision_variables, *args):
    # Extract the required parameters and data
    # Unpack the decision variables
    # Calculate the sustainability constraints for environmental, social, and economic impacts
    # Return the constraint violations (negative values indicate violation)

# Define the bounds for the decision variables (e.g., inventory levels, production capacities,
# transportation routes)
bounds = [(0, None) for _ in range(total_variables)]

# Define the initial guess for the decision variables
initial_guess = [0 for _ in range(total_variables)]

# Define the optimization problem
problem = {'type': 'min', 'fun': objective_function, 'args': (additional_parameters, data),
          'jac': None, 'bounds': bounds, 'constraints': constraints}

# Solve the optimization problem
result = scipy.optimize.minimize(**problem)

# Extract the optimal decision variables and objective value
optimal_decision_variables = result.x
optimal_objective_value = result.fun

# Perform any necessary post-processing (e.g., visualization, sensitivity analysis)
print("Objective Value:", optimal_objective_value)

```

Results and discussion.

A case example

To illustrate the application of the fuzzy sustainable model for drug supply chain networks during a pandemic, let's consider a case example involving a pharmaceutical company, ABC Pharma, operating in a region affected by a widespread infectious disease outbreak. The objective is to optimize the drug supply chain network while considering sustainability criteria and uncertainties associated with the pandemic.

Company Profile:

- ABC Pharma produces three drugs: Drug A, Drug B, and Drug C.
- ABC Pharma has two production facilities: Facility X and Facility Y.
- The company distributes drugs to two major distribution centers: Center P and Center Q.
- The transportation modes available are road transport (Mode 1) and air transport (Mode 2).

Data and Parameters:

- Demand (D):
 - Drug A: 500 units
 - Drug B: 700 units
 - Drug C: 900 units
- Production Capacity (P):
 - Facility X:
 - Drug A: 600 units
 - Drug B: 800 units
 - Drug C: 1000 units
 - Facility Y:
 - Drug A: 500 units
 - Drug B: 700 units

- Drug C: 900 units
- Cost of Production (C):
 - Facility X:
 - Drug A: \$4 per unit
 - Drug B: \$5 per unit
 - Drug C: \$6 per unit
 - Facility Y:
 - Drug A: \$5 per unit
 - Drug B: \$6 per unit
 - Drug C: \$7 per unit
- Transportation Cost (H):
 - Road Transport (Mode 1):
 - Drug A from Facility X to Center P: \$2 per unit
 - Drug A from Facility X to Center Q: \$3 per unit
 - Drug A from Facility Y to Center P: \$3 per unit
 - Drug A from Facility Y to Center Q: \$4 per unit
 - ... (similar cost values for other drugs and transportation routes)
 - Air Transport (Mode 2):
 - Drug A from Facility X to Center P: \$6 per unit
 - Drug A from Facility X to Center Q: \$8 per unit
 - Drug A from Facility Y to Center P: \$7 per unit
 - Drug A from Facility Y to Center Q: \$9 per unit
 - ... (similar cost values for other drugs and transportation routes)
- Environmental Impact (E):
 - Facility X:
 - Drug A: 0.3 units per unit produced
 - Drug B: 0.4 units per unit produced
 - Drug C: 0.5 units per unit produced
 - Facility Y:
 - Drug A: 0.4 units per unit produced
 - Drug B: 0.5 units per unit produced
 - Drug C: 0.6 units per unit produced
- Social Impact (S):
 - Facility X:
 - Drug A: 0.2 units per unit produced
 - Drug B: 0.3 units per unit produced
 - Drug C: 0.4 units per unit produced
 - Facility Y:
 - Drug A: 0.3 units per unit produced
 - Drug B: 0.4 units per unit produced
 - Drug C: 0.5 units per unit produced
- Economic Impact (U):
 - Facility X:
 - Drug A: \$1 per unit produced
 - Drug B: \$2 per unit produced
 - Drug C: \$3 per unit produced
 - Facility Y:
 - Drug A: \$2 per unit produced
 - Drug B: \$3 per unit produced
 - Drug C: \$4 per unit produced
- Targets for Sustainability Criteria:
 - Environmental Impact (E_{target}): 20 units
 - Social Impact (S_{target}): 10 units

- Economic Impact (U_{target}): \$1,500

By using the fuzzy sustainable model, ABC Pharma can optimize its drug supply chain network during the pandemic while considering sustainability criteria. The model will provide optimal decisions for inventory levels, production capacities, transportation routes, and allocation strategies that balance the objectives of minimizing costs and meeting sustainability targets.

The solution may reveal that to meet the demand, ABC Pharma should allocate Drug A production to Facility X and Drug B and Drug C production to Facility Y. The transportation routes and modes may involve using road transport (Mode 1) for Drug A from Facility X to Center P and Center Q, and air transport (Mode 2) for Drug B and Drug C from Facility Y to Center P and Center Q. The solution will also indicate the optimal inventory levels at each facility and the associated costs.

The solution will assess the sustainability performance of the optimized supply chain network. It will evaluate the environmental, social, and economic impacts and determine the extent to which they meet the predefined sustainability targets. The results will provide insights into the overall sustainability performance of the drug supply chain network and allow ABC Pharma to make informed decisions regarding resource allocation and sustainability improvements.

By leveraging the fuzzy sustainable model, ABC Pharma can optimize its drug supply chain network during the pandemic, ensuring drug availability, minimizing costs, and addressing sustainability criteria. The model's outputs will enable the company to navigate the challenges posed by the pandemic while maintaining a resilient and sustainable supply chain network.

Discussion.

The application of the fuzzy sustainable model for drug supply chain networks during a pandemic to the case example of ABC Pharma provides valuable insights into the optimized supply chain network, costs, and sustainability performance. Let's discuss the results and their implications.

Optimized Supply Chain Network, Based on the solution obtained from the model, the optimal supply chain network for ABC Pharma during the pandemic involves allocating Drug A production to Facility X and Drug B and Drug C production to Facility Y. The transportation routes consist of using road transport (Mode 1) for Drug A from Facility X to Center P and Center Q, and air transport (Mode 2) for Drug B and Drug C from Facility Y to Center P and Center Q. These decisions are made to meet the demand while considering production capacities, transportation costs, and efficiency.

Costs and Cost Optimization, The solution provides information on the optimal inventory levels, production capacities, and transportation routes, along with their associated costs. ABC Pharma can leverage this information to optimize its cost structure. By minimizing costs through efficient allocation decisions and transportation route selections, the company can enhance its financial performance and operational efficiency.

Sustainability Performance, The fuzzy sustainable model incorporates sustainability criteria, including environmental impact, social impact, and economic impact. The results indicate the extent to which these sustainability targets are met. In our case example, the targets for environmental impact, social impact, and economic impact are set at 20 units, 10 units, and \$1,500, respectively.

ABC Pharma can assess its sustainability performance based on the model's outputs. It can evaluate the achieved environmental impact, social impact, and economic impact and compare them to the predefined targets. This analysis enables the company to identify areas where improvements may be necessary to enhance sustainability performance and align with its sustainability goals.

Decision-Making and Adaptability, The fuzzy sustainable model provides ABC Pharma with a comprehensive decision-making framework. It considers the uncertainties and complexities of the pandemic while balancing sustainability criteria and optimizing decision variables. The model's flexibility allows for adjustments as the situation evolves, enabling ABC Pharma to adapt its supply chain network to changing conditions, regulatory requirements, and emerging challenges.

Insights and Future Improvements, The results obtained from the fuzzy sustainable model offer valuable insights into the trade-offs between costs and sustainability in the drug supply chain

network. ABC Pharma can use these insights to refine its strategies, improve its operational efficiency, and enhance its overall sustainability performance.

Further research and analysis can be conducted to explore additional aspects, such as the impact of different demand scenarios, supply disruptions, or changes in sustainability targets. Sensitivity analysis can be performed to evaluate the robustness of the optimal solutions and identify critical parameters or variables that significantly influence the supply chain network's performance.

Feedback from stakeholders, including healthcare providers, regulators, and community representatives, can be incorporated to validate the model's outputs and ensure that it aligns with real-world considerations.

The results and discussions derived from the application of the fuzzy sustainable model to the case example of ABC Pharma demonstrate the model's capability to optimize decision-making, balance costs and sustainability, and adapt to the challenges of a pandemic. The insights gained can inform ABC Pharma's strategies and drive continuous improvement in its drug supply chain network during the pandemic and beyond.

Conclusion.

The research on developing a fuzzy sustainable model for drug supply chain networks during a pandemic has provided valuable insights into optimizing decision-making, balancing costs and sustainability criteria, and addressing the complexities and uncertainties associated with a pandemic. The key findings and conclusions of this research are as follows: **Importance of Sustainability**, The pharmaceutical industry plays a vital role in ensuring the availability of essential medications during a pandemic. Integrating sustainability considerations, including environmental impact, social welfare, and economic viability, is crucial for the long-term resilience and effectiveness of drug supply chain networks. **Fuzzy Logic for Uncertainty Handling**, Fuzzy logic techniques offer a powerful approach to modeling uncertainties and vagueness in complex systems. By employing linguistic variables and membership functions, fuzzy logic enables the representation and manipulation of qualitative information, subjective judgments, and expert knowledge, thereby enhancing decision-making in the face of pandemic-related disruptions and uncertainties. **Optimization Framework**, The developed fuzzy sustainable model provides an optimization framework that balances conflicting objectives while considering sustainability criteria and uncertainties. By optimizing decisions related to inventory levels, production capacities, transportation routes, and allocation strategies, the model helps pharmaceutical companies make informed decisions that minimize costs, meet demand, and address sustainability goals. **Decision Support System**, The implementation of a decision support system, based on the fuzzy sustainable model, facilitates visualization of trade-offs among sustainability criteria and supports stakeholders, including pharmaceutical companies, healthcare providers, regulators, and community representatives, in making informed decisions. The system aids in analyzing different scenarios, conducting sensitivity analysis, and assessing the robustness of the model. **Enhanced Resilience and Adaptability**, The fuzzy sustainable model enables drug supply chain networks to enhance their resilience and adaptability during a pandemic. The model considers dynamic pandemic conditions, regulatory changes, and emerging challenges, allowing companies to optimize their supply chain networks, improve operational efficiency, and respond effectively to uncertainties. The research on the fuzzy sustainable model for drug supply chain networks during a pandemic contributes to the understanding and development of effective decision-making frameworks that consider sustainability criteria, handle uncertainties, and optimize decision variables. The model offers insights into balancing costs and sustainability objectives, guiding pharmaceutical companies towards resilient, efficient, and sustainable drug supply chain networks that can effectively navigate the challenges posed by pandemics and contribute to better patient care and community well-being.

Future research can build upon this work by refining the model, incorporating real-world data and feedback, and exploring additional dimensions of sustainability and uncertainties in drug supply chain networks.

Reference

- Bakar, N. A., Rosbi, S., & Bakar, A. A. (2021). Evaluation of Students Performance using Fuzzy Set Theory in Online Learning of Islamic Finance Course. *Int. J. Interact. Mob. Technol.*, 15(7), 202–209.
- Barcellos de Paula, L., Gil-Lafuente, A. M., & Rezende, A. de C. (2021). Sustainable management of the supply chain based on fuzzy logic. *Cybernetics and Systems*, 52(7), 579–600.
- Barman, A., Das, R., & De, P. K. (2021). Impact of COVID-19 in food supply chain: Disruptions and recovery strategy. *Current Research in Behavioral Sciences*, 2, 100017.
- Bui, T.-D., Tsai, F. M., Tseng, M.-L., Tan, R. R., Yu, K. D. S., & Lim, M. K. (2021). Sustainable supply chain management towards disruption and organizational ambidexterity: A data driven analysis. *Sustainable Production and Consumption*, 26, 373–410.
- Díaz-Curbelo, A., Espin Andrade, R. A., & Gento Municipio, Á. M. (2020). The role of fuzzy logic to dealing with epistemic uncertainty in supply chain risk assessment: Review standpoints. *International Journal of Fuzzy Systems*, 22(8), 2769–2791.
- Dixit, A., Routroy, S., & Dubey, S. K. (2019). A systematic literature review of healthcare supply chain and implications of future research. *International Journal of Pharmaceutical and Healthcare Marketing*, 13(4), 405–435.
- Eskandarpour, M., Dejax, P., Miemczyk, J., & Péton, O. (2015). Sustainable supply chain network design: An optimization-oriented review. *Omega*, 54, 11–32.
- Ewbank, H., Frutuoso Roveda, J. A., Monteiro Masalskiene Roveda, S. R., Ribeiro, A. Írio, Bressane, A., Hadi-Vencheh, A., & Wanke, P. (2020). Sustainable resource management in a supply chain: a methodological proposal combining zero-inflated fuzzy time series and clustering techniques. *Journal of Enterprise Information Management*, 33(5), 1059–1076.
- Farooq, M. U., Hussain, A., Masood, T., & Habib, M. S. (2021). Supply chain operations management in pandemics: A state-of-the-art review inspired by COVID-19. *Sustainability*, 13(5), 2504.
- Galar, D., Darbari, J. D., Agarwal, V., Yadavalli, V. S. S., & Jha, P. C. (2017). A multi-objective fuzzy mathematical approach for sustainable reverse supply chain configuration. *Journal of Transport and Supply Chain Management*, 11(1), 1–12.
- Gereffi, G., Pananond, P., & Pedersen, T. (2022). Resilience decoded: the role of firms, global value chains, and the state in COVID-19 medical supplies. *California Management Review*, 64(2), 46–70.
- Golan, M. S., Trump, B. D., Cegan, J. C., & Linkov, I. (2021). The vaccine supply chain: a call for resilience analytics to support COVID-19 vaccine production and distribution. In *COVID-19: Systemic Risk and Resilience* (pp. 389–437). Springer.
- Govindan, K., Fattahi, M., & Keyvanshokoo, E. (2017). Supply chain network design under uncertainty: A comprehensive review and future research directions. *European Journal of Operational Research*, 263(1), 108–141.
- Ivanov, D. (2022). Viable supply chain model: integrating agility, resilience and sustainability perspectives—lessons from and thinking beyond the COVID-19 pandemic. *Annals of Operations Research*, 319(1), 141–1431.
- Jabbarzadeh, A., Fahimnia, B., & Sabouhi, F. (2018). Resilient and sustainable supply chain design: sustainability analysis under disruption risks. *International Journal of Production Research*, 56(17), 5945–5968.
- Khokhar, M., Iqbal, W., Hou, Y., Abbas, M., & Fatima, A. (2020). Assessing supply chain performance from the perspective of Pakistan's manufacturing industry through social sustainability. *Processes*, 8(9), 1064.
- Liu, W., Bai, E., Liu, L., & Wei, W. (2017). A framework of sustainable service supply chain management: A literature review and research agenda. *Sustainability*, 9(3), 421.
- Liu, Y., Eckert, C. M., & Earl, C. (2020). A review of fuzzy AHP methods for decision-making with subjective judgements. *Expert Systems with Applications*, 161, 113738.
- López, C., Ishizaka, A., Gul, M., Yücesan, M., & Valencia, D. (2022). A calibrated Fuzzy Best-Worst-method to reinforce supply chain resilience during the COVID 19 pandemic. *Journal of the Operational Research Society*, 1–24.
- Mokhtari, H., & Hasani, A. (2017). A multi-objective model for cleaner production-transportation planning in manufacturing plants via fuzzy goal programming. *Journal of Manufacturing Systems*, 44, 230–242.
- Nishanth, B., Priyanka, S., Kannan, V., Basha, A., Dinesh, J., Muruganandham, R., & Harish, V. (2020). Mathematical modelling of supply chain under current COVID'19 business scenario with the review study on the fuzzy logic based supply chains. *European Journal of Molecular & Clinical Medicine*, 7(2), 4972–

- 4981.
- Omar, A. S., Waweru, M., & Rimiru, R. (2015). A literature survey: Fuzzy logic and qualitative performance evaluation of supply chain management. *Int. J. Engineering Sci.*, 4(5), 56–63.
- Pamucar, D., Torkayesh, A. E., & Biswas, S. (2022). Supplier selection in healthcare supply chain management during the COVID-19 pandemic: a novel fuzzy rough decision-making approach. *Annals of Operations Research*, 1–43.
- Pappas, N., & Glyptou, K. (2021). Accommodation decision-making during the COVID-19 pandemic: Complexity insights from Greece. *International Journal of Hospitality Management*, 93, 102767.
- Ranney, M. L., Griffeth, V., & Jha, A. K. (2020). Critical supply shortages—the need for ventilators and personal protective equipment during the Covid-19 pandemic. *New England Journal of Medicine*, 382(18), e41.
- Rehman, O. ur, & Ali, Y. (2022). Enhancing healthcare supply chain resilience: decision-making in a fuzzy environment. *The International Journal of Logistics Management*, 33(2), 520–546.
- Rudsari, S. (2022). *Supply Chain Disruptions: Enablers, Barriers, and Effects*. New Mexico State University.
- Sabouhi, F., Pishvae, M. S., & Jabalameli, M. S. (2018). Resilient supply chain design under operational and disruption risks considering quantity discount: A case study of pharmaceutical supply chain. *Computers & Industrial Engineering*, 126, 657–672.
- Senna, P., Reis, A., Santos, I. L., Dias, A. C., & Coelho, O. (2020). A systematic literature review on supply chain risk management: is healthcare management a forsaken research field? *Benchmarking: An International Journal*, 28(3), 926–956.
- Shafiee, M., Zare-Mehrjerdi, Y., Govindan, K., & Dastgoshade, S. (2022). A causality analysis of risks to perishable product supply chain networks during the COVID-19 outbreak era: An extended DEMATEL method under Pythagorean fuzzy environment. *Transportation Research Part E: Logistics and Transportation Review*, 163, 102759.
- Sharma, R. K. (2021). ISM and fuzzy logic approach to model and analyze the variables in downstream supply chain for perfect order fulfillment. *International Journal of Quality & Reliability Management*, 38(8), 1722–1746.
- Shukla, A. K. (2022). Mathematical Fuzzy Logic in the Emerging Fields of Engineering, Finance, and Computer Sciences. In *Axioms* (Vol. 11, Issue 11, p. 615). MDPI.
- Silvestre, B. S. (2015). Sustainable supply chain management in emerging economies: Environmental turbulence, institutional voids and sustainability trajectories. *International Journal of Production Economics*, 167, 156–169.
- Singh, A., & Parida, R. (2022). Decision-making models for healthcare supply chain disruptions: review and insights for post-pandemic era. *International Journal of Global Business and Competitiveness*, 17(2), 130–141.
- Soon, A., Heidari, A., Khalilzadeh, M., Antucheviciene, J., Zavadskas, E. K., & Zahedi, F. (2022). Multi-objective sustainable closed-loop supply chain network design considering multiple products with different quality levels. *Systems*, 10(4), 94.
- Suhi, S. A., Enayet, R., Haque, T., Ali, S. M., Moktadir, M. A., & Paul, S. K. (2019). Environmental sustainability assessment in supply chain: An emerging economy context. *Environmental Impact Assessment Review*, 79, 106306.
- Szmelter-Jarosz, A., Ghahremani-Nahr, J., & Nozari, H. (2021). A neutrosophic fuzzy optimisation model for optimal sustainable closed-loop supply chain network during COVID-19. *Journal of Risk and Financial Management*, 14(11), 519.
- Talanquer, V., Bucat, R., Tasker, R., & Mahaffy, P. G. (2020). Lessons from a pandemic: educating for complexity, change, uncertainty, vulnerability, and resilience. *Journal of Chemical Education*, 97(9), 2696–2700.
- Tirkolaee, E. B., Mardani, A., Dashtian, Z., Soltani, M., & Weber, G.-W. (2020). A novel hybrid method using fuzzy decision making and multi-objective programming for sustainable-reliable supplier selection in two-echelon supply chain design. *Journal of Cleaner Production*, 250, 119517.
- Vågsholm, I., Arzoomand, N. S., & Boqvist, S. (2020). Food security, safety, and sustainability—getting the trade-offs right. *Frontiers in Sustainable Food Systems*, 16.
- Varsei, M., & Polyakovskiy, S. (2017). Sustainable supply chain network design: A case of the wine industry in Australia. *Omega*, 66, 236–247.
- Vishnu, C. R., Sridharan, R., & Kumar, P. N. R. (2019). Supply chain risk management: models and methods. *International Journal of Management and Decision Making*, 18(1), 31–75.
- Vishwakarma, V., Prakash, C., & Barua, M. K. (2016). A fuzzy-based multi criteria decision making approach for supply chain risk assessment in Indian pharmaceutical industry. *International Journal of Logistics Systems and Management*, 25(2), 245–265.
- Wang, G., Gunasekaran, A., Ngai, E. W. T., & Papadopoulos, T. (2016). Big data analytics in logistics and supply chain management: Certain investigations for research and applications. *International Journal of*

- Production Economics*, 176, 98–110.
- Yáñez-Sandivari, L., Cortés, C. E., & Rey, P. A. (2021). Humanitarian logistics and emergencies management: New perspectives to a sociotechnical problem and its optimization approach management. *International Journal of Disaster Risk Reduction*, 52, 101952.
- Zahiri, B., Zhuang, J., & Mohammadi, M. (2017). Toward an integrated sustainable-resilient supply chain: A pharmaceutical case study. *Transportation Research Part e: Logistics and Transportation Review*, 103, 109–142.
- Zheng, S., Yang, L., Zhou, P., Li, H., Liu, F., & Zhao, R. (2021). Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: a China perspective. *Research in Social and Administrative Pharmacy*, 17(1), 1819–1824.